Clinical Experience With Deferiprone Treatment for Friedreich Ataxia. (July 2016)

• Record Type: Journal Article
• Authors: Elincx-Benizri, Sandra; Glik, Amir; Merkel, Drorit; Arad, Michael; Freimark, Dov; Kozlova, Evgenia; Cabantchik, Ioav; Hassin-Baer, Sharon
• Is Part Of: Journal of child neurology. Volume 31:Number 8(2016:Aug.)
• Page Start: 1036
• Page End: 1040
• Publication Date: 2016-07
• Subjects: Friedreich ataxia -- iron chelation -- deferiprone -- idebenone -- cardiomyopathy; Nervous system -- Diseases -- Periodicals; 618.928
• DOI: 10.1177/0883073816636087
• Languages: English
• ISSNs: 0883-0738

Abstract

Friedreich ataxia is an inherited disorder characterized by degeneration of the peripheral and central nervous system and hypertrophic cardiomyopathy. Homozygous mutations in the frataxine (FXN) gene reduce expression of frataxin and cause accumulation of iron in the mitochondria. Deferiprone, an oral iron chelator, has been shown effective in cell and animal models of Friedreich ataxia. The results of a 6-month randomized, double blind placebo-controlled study suggested that deferiprone 20 mg/kg/day may reduce disease progression. The authors present their experience of 5 Friedreich ataxia patients treated with deferiprone (20 mg/kg/day), in addition to idebenone treatment, followed over a period of 10-24 months, under off-label authorization. The patients were monitored for laboratory parameters, cardiac assessment, neurological evaluations, and quality of life. The authors conclude that combined therapy of a low dose of deferiprone with idebenone is relatively safe, might improve neurological function, and seems to improve heart hypertrophy, warranting further studies.